Time (hours) Animal Groups
Control (Group I) DOCA salt (Group II) DOCA salt + Formulation
(Group III)
DOCA salt + Pure Drug
(Group IV)
Systolic BP Diastolic BP Systolic BP Diastolic BP Systolic BP Diastolic BP Systolic BP Diastolic BP
0 hr 120 ± 0.40 91 ± 0.7 162 ± 1.35* 119 ± 1.08* 164 ± 1.08# 118 ± 0.82# 163 ± 0.71## 119 ± 0.42##
1 hr 119 ± 0.82 92 ± 1.23 164 ± 0.81* 120 ± 0.58* 153 ± 1.58# 115 ± 0.91# 142 ± 1.08## 108 ± 1.07##
2 hr 121 ± 0.7 90 ± 1.08 162 ± 1.23* 121 ± 0.71* 148 ± 0.41# 109 ± 0.912# 131 ± 1.59## 102 ± 0.41##
6 hr 120 ±0.91 91 ± 0.40 163 ± 2.34* 120 ± 1.47* 139 ± 1.23# 103 ± 0.57# 132 ± 1.68## 101 ± 0.71##
12 hr 122 ± 1.08 91 ± 1.22 162 ± 0.41* 119 ± 1.68* 129 ± 0.91# 97 ± 1.23# 137 ± 1.0## 100 ± 1.04##
24 hr 120 ± 1.0 92 ± 0.82 163 ± 1* 119 ± 1.15* 126 ± 0.41# 94 ± 1.08# 139 ± 0.87## 101 ± 0.85##
BP- Blood pressure, DOCA- Deoxycorticosterone acetate.
Data expressed in Mean ± SEM. n = 4. Statistical analysis is done by One-way Analysis of Variance followed by Tukey’s Multiple Comparison Test. *P<0.001: when compared with Control Group; #P<0.05: When compared with DOCA Treated group; ##P<0.001: when compared with DOCA Treated group.
Table 4: In vivo studies of hydralazine hydrochloride microspheres (formulation F6) for antihypertensive effect.
Goto home»